LSL Pharma Group Inc (TSE:LSL) has released an update.
LSL Pharma Group Inc. has reported a revenue increase of 22% in FY-2023, reaching $10.0 million, alongside an improved Q4 EBITDA from a $2.2 million loss in Q4-2022 to a $0.3 million profit in Q4-2023. Despite these gains, the company faced a net loss of $8.5 million in FY-2023, slightly higher than the previous year’s $8.1 million loss. These results come after the company’s strategic financial movements, including over $20 million in gross financings and a substantial debt reduction.
For further insights into TSE:LSL stock, check out TipRanks’ Stock Analysis page.
